TY - JOUR
T1 - Achieving consensus on patient-reported outcome measures in clinical practice for inflammatory skin disorders
AU - International Dermatology Outcome Measures
AU - American Academy of Dermatology
AU - Perez-Chada, Lourdes
AU - Taliercio, Vanina L.
AU - Gottlieb, Alice B.
AU - Van Beek, Marta
AU - Duffin, Kristina Callis
AU - Reeder, Margo
AU - Merola, Joseph F.
AU - Swerlick, Robert A.
N1 - Funding Information:
Supported by International Dermatology Outcome Measures and the American Academy of Dermatology .
Funding Information:
Conflicts of interest: Dr Gottlieb is an advisor/consultant for Janssen Inc, Celgene, Beiersdorf, BMS, AbbVie, UCB, Novartis, Incyte Corporation, Lilly, Reddy Labs, Valeant, Dermira, Allergan, Sun Pharmaceutical Industries, XBiotech, Leo, Avotres Therapeutics, and Boeringer Ingelheim. She received research or educational grants from Janssen , Incyte Corporation , XBiotech , Novartis , Boeringer Ingelheim , and UCB . In addition, she participated in the development of the National Psoriasis Foundation Psoriasis Score, an instrument discussed in the present study. Dr Duffin has served on the advisory board or as a consultant or investigator for Stiefel, Novartis, Amgen, AbbVie, Celgene, Lilly, Ortho, Pfizer, Janssen, and Boehringer Ingelheim. In addition, she has participated in validation studies of the IGAxBSA, an instrument discussed in the present study. Dr Merola has served as a consultant or investigator or is on the advisory board for Merck, AbbVie, Eli Lilly, Incyte, Janssen, UCB, GlaxoSmithKline, Almirall, Pfizer, Sun Pharma, Novartis, Burrage Capital Mgmt, Aclaris, Leo, Celgene, and Dermavent. Dr Perez-Chada, Dr Taliercio, Dr Van Beek, Dr Margo Reeder, and Dr Swerlick did not have relevant financial conflicts to disclose.
Publisher Copyright:
© 2019 American Academy of Dermatology, Inc.
PY - 2023/1
Y1 - 2023/1
N2 - Background: International Dermatology Outcome Measures and the American Academy of Dermatology recently agreed on a physician-reported global severity measure to demonstrate quality of care in inflammatory dermatoses. Objective: Because patient-reported outcome measures are also important, we aimed to achieve consensus on 1 of these measures for clinical practice. Methods: Patients and providers participated in a consensus-building study involving a modified-Delphi technique. Voting was focused on identifying a minimal set of assessments for clinical practice, patient global assessments (PtGAs), Skindex instruments, and final instrument selection for quality improvement. Results: Among 53 stakeholders, >70% agreed that identification of patient goals, assessment of treatment harm, and assessment of the adequacy of treatment response were the minimal assessments needed for clinical practice. The most preferred PtGA was a 5-point PtGA (scale 0-4; 0 = clear, 4 = severe) having an optional check-box for worst ever. A new metric to assess change since treatment initiation, which we called a trajectory measure, was proposed. Stakeholders preferred Skindex instruments over PtGAs and a trajectory measure for clinical practice. Limitations: A small number of patients and caregivers were involved and a consensus was not reached on all items. Conclusion: PtGAs as standalone measures do not adequately capture the patient's assessment of disease severity or the effect of care. The combination of a PtGA with a Skindex instrument or another measure of health-related quality of life might provide a more comprehensive evaluation of patients in clinical practice.
AB - Background: International Dermatology Outcome Measures and the American Academy of Dermatology recently agreed on a physician-reported global severity measure to demonstrate quality of care in inflammatory dermatoses. Objective: Because patient-reported outcome measures are also important, we aimed to achieve consensus on 1 of these measures for clinical practice. Methods: Patients and providers participated in a consensus-building study involving a modified-Delphi technique. Voting was focused on identifying a minimal set of assessments for clinical practice, patient global assessments (PtGAs), Skindex instruments, and final instrument selection for quality improvement. Results: Among 53 stakeholders, >70% agreed that identification of patient goals, assessment of treatment harm, and assessment of the adequacy of treatment response were the minimal assessments needed for clinical practice. The most preferred PtGA was a 5-point PtGA (scale 0-4; 0 = clear, 4 = severe) having an optional check-box for worst ever. A new metric to assess change since treatment initiation, which we called a trajectory measure, was proposed. Stakeholders preferred Skindex instruments over PtGAs and a trajectory measure for clinical practice. Limitations: A small number of patients and caregivers were involved and a consensus was not reached on all items. Conclusion: PtGAs as standalone measures do not adequately capture the patient's assessment of disease severity or the effect of care. The combination of a PtGA with a Skindex instrument or another measure of health-related quality of life might provide a more comprehensive evaluation of patients in clinical practice.
KW - IDEOM
KW - acne
KW - atopic dermatitis
KW - inflammatory dermatoses
KW - psoriasis
KW - quality measure
KW - quality of care
UR - http://www.scopus.com/inward/record.url?scp=85144041051&partnerID=8YFLogxK
U2 - 10.1016/j.jaad.2019.09.008
DO - 10.1016/j.jaad.2019.09.008
M3 - Article
C2 - 31525439
AN - SCOPUS:85144041051
SN - 0190-9622
VL - 88
SP - 86
EP - 93
JO - Journal of the American Academy of Dermatology
JF - Journal of the American Academy of Dermatology
IS - 1
ER -